Nanodelivery platform for antibody drugs targeting NHL

针对 NHL 的抗体药物纳米递送平台

基本信息

  • 批准号:
    9947904
  • 负责人:
  • 金额:
    $ 46.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-18 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Therapeutic monoclonal antibodies (mAbs), such as rituximab, have produced significant improvement in the mortality rates of patients with non-Hodgkin lymphoma (NHL). However, fundamental issues with antibody therapy such as poor tissue penetration of antibodies, non-specific antibody delivery, escape from antibody recognition, and eliciting of an immune response against antibodies, remain unsolved. We have developed a nanodelivery platform for macromolecules whereby an individual “cargo” is encapsulated within a thin polymer shell, termed a “nanocapsule”. Our platform is highly adaptable, allowing us to customize various properties, including cell surface affinity, cargo immunogenicity, cargo release rates, in vivo circulation times, and biodistribution, by altering the surface chemistry of the nanocapsules. Our nanocapsules are inert, highly stable, and resistant to protein adsorption, which are properties necessary for increased blood circulation times and elimination of cargo immunogenicity. Importantly, our nanocapsules do not enter into cells due to their neutral surface charge, but can still efficiently enter the central nervous system (CNS) and reduce cancer burden in the brain and eyes of human Burkitt lymphoma xenograft mice; this could be because the retina is part of the CNS. These indicate that they are ideal carrier vehicles for extracellular delivery of therapeutic mAbs to locations such as the brain and eyes, where penetration of antibodies is extremely poor. The ultimate goal of the proposed studies is to establish a clinically relevant in vivo delivery platform for therapeutic mAb drugs, thus enabling efficient elimination of cancers, especially those that have metastasized into the CNS or eyes.
项目总结 治疗性单抗(MAbs),如利妥昔单抗,已在治疗中产生显著改善 非霍奇金淋巴瘤(NHL)患者死亡率。然而,抗体的基本问题 治疗如抗体组织穿透力差,非特异性抗体传递,逃避抗体 识别和激发针对抗体的免疫反应仍然没有解决。我们已经开发出一种 用于大分子的纳米递送平台,通过该平台,单独的“货物”被封装在薄聚合物中 壳,被称为“纳米胶囊”。我们的平台具有很强的适应性,允许我们定制各种属性, 包括细胞表面亲和力、货物免疫原性、货物释放率、体内循环时间和 生物分布,通过改变纳米胶囊的表面化学。我们的纳米胶囊是惰性的,高度稳定, 和抗蛋白质吸附,这是增加血液循环时间和 消除货物的免疫原性。重要的是,我们的纳米胶囊不会因为它们的中性而进入细胞 表面电荷,但仍能有效进入中枢神经系统(CNS),减轻癌症负担 人类Burkitt淋巴瘤异种移植小鼠的大脑和眼睛;这可能是因为视网膜是中枢神经系统的一部分。 这表明它们是理想的载体载体,用于细胞外将治疗性单抗输送到如下位置 如大脑和眼睛,那里的抗体穿透性极差。建议的最终目标是 研究是建立一个具有临床相关性的治疗性单抗药物的体内给药平台,从而使 有效地消除癌症,特别是那些已经转移到中枢神经系统或眼睛的癌症。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Masakazu Kamata其他文献

Masakazu Kamata的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Masakazu Kamata', 18)}}的其他基金

Eradication of brain/CNS HIV reservoirs via anti-HIV gene-modified macrophages
通过抗 HIV 基因修饰的巨噬细胞根除大脑/中枢神经系统 HIV 储存库
  • 批准号:
    10589937
  • 财政年份:
    2022
  • 资助金额:
    $ 46.39万
  • 项目类别:
Nanodelivery platform for antibody drugs targeting NHL
针对 NHL 的抗体药物纳米递送平台
  • 批准号:
    10443535
  • 财政年份:
    2018
  • 资助金额:
    $ 46.39万
  • 项目类别:
Gene-engineered stem cell memory T-cells with anti-HIV chimeric antigen receptors
具有抗 HIV 嵌合抗原受体的基因工程干细胞记忆 T 细胞
  • 批准号:
    9317405
  • 财政年份:
    2016
  • 资助金额:
    $ 46.39万
  • 项目类别:
Gene-Engineered Stem Cell Memory T-Cells With Anti-HIV Chimeric Antigen Receptors
具有抗 HIV 嵌合抗原受体的基因工程干细胞记忆 T 细胞
  • 批准号:
    10091936
  • 财政年份:
    2016
  • 资助金额:
    $ 46.39万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 46.39万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 46.39万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 46.39万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 46.39万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 46.39万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 46.39万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 46.39万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 46.39万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 46.39万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 46.39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了